

DIAGNOSI MOLECOLARE E RICERCA SULLA F.O.P. IN ITALIA

Verbania, 16-17 Aprile, 2010

Roberto Ravazzolo

Renata Bocciardi

Marzia Mura

Francesca Giacopelli

Serena Cappato

Laboratorio di Genetica Molecolare

Istituto G. Gaslini Genova

Dipartimento di Scienze Pediatriche

Università di Genova



Il Laboratorio esegue la diagnosi molecolare mediante ricerca di mutazioni nel gene ACVR1 su individui con diagnosi clinica di F.O.P. o con sospetta diagnosi

Summary of the clinical features and molecular analysis of the presented FOP patients set.


	Pt	Age	Sex	Age Ossification onset	Great toe malf.	Mutation	Other
1	FOP1	33 y	M	na	y	c.617G>A, nd	
2	FOP2	5 y	M	15 months	y	c.617G>A, <i>de novo</i>	Hydrocephalus secondary to a posterior bulbar expansive lesion of unknown origin (surgical correction)
3	FOP3	10 y	F	4 y	y	c.617G>A, <i>de novo</i>	
4	FOP4	5 y	F	20 months	y	c.617G>A, <i>de novo</i>	
5	FOP5	n.a.	M	8 y	y	c.617G>A, nd	
6	FOP6	29 y	F	6 y	y	c.617G>A, nd	
7	FOP7	28 y	F	11 y	y	c.617G>A, nd	
8	FOP8	50 y	F	11 y	y	c.617G>A, nd	
9	FOP9	45 y	M	3 y	y	c.617G>A, nd	
10	FOP10	36 y	M	14 y	y	c.617G>A, nd	
11	FOP12	9 y	M	6 months	y	c.617G>A, nd	
12	FOP13	22 y	F	4 y	No	c.774G>C, <i>de novo</i> , R258S	c.44C>G dbSNP rs13406336, inherited
13	FOP14	49 y	M	5 y	y	c.617G>A, nd	Episodic seizures
14	FOP15	37 y	M	4	y	c.617G>A, nd	
15	FOP17	9 y	M	6 y	y	c.617G>A, nd	
16	FOP18	17 y	F	na	Short hallux	c.617G>A, nd	Fusion of C4-C5, osseous dysplasia
17	FOP20	44 y	F	14 y	No	c.774G>C, <i>de novo</i> , R258S	Vitamin D deficiency, thyroid goiter
18	FOP22	38 y	F	9 months	y	c.617G>A, nd	
19	FOP23	11 y	M	5 y	hypoplastic	c.617G>A, nd	Neck stiffness, NOGGIN neg
20	FOP24	13 y	M	13 y	y	c.619C>G, <i>de novo</i> , Q207E	Malformed shortened thumbs
21	FOP27	13y	M	8 y	y	c.774G>T, R258S	Pt from Morocco
22	FOP29	15 m	M	> 1 y	y	c.617G>A, R206H	Pt from UK
23	FOP30	12 y	F	-	y	c.617G>A, R206H	
24	FOP31	49 y	F	7 y	y	c.617G>A, nd	Dysmorphic thumbs
25	FOP34	5 y	F	?	y	c.774G>C, <i>de novo</i> , R258S	Ossification head and neck

Pt, patient code; nd, mutation origin not determined; na, not available; 36 patients have been screened, 25 with confirmation of the clinical diagnosis, 11 with exclusion of FOP.

Age stratification	
0-10 years	4
11-20 years	5
21-30 years	3
31-40 years	4
41-50 years	4
51-60 years	1
	21



Age Ossification Onset	
0-10 years	13
11-20 years	5
Not available (NA)	4
	22



Ricerca sui meccanismi della F.O.P.

Si esegue grazie ai contributi economici di

- F.O.P. Italia
- Ministero dell'Università
- Ministero della Salute

Regolazione del gene ACVR1

La conoscenza dei meccanismi di regolazione permette di comprendere come è controllata la quantità di espressione del gene

Nella F.O.P. la mutazione del gene è associata a un eccesso di funzione dell'intera via di segnalazione delle BMP

Un modo per limitare la funzione del gene e della via funzionale ad esso collegata potrebbe basarsi su un intervento nel meccanismo che regola la sua espressione

Analogamente alla maggior parte dei geni umani, anche l'espressione di ACVR1 viene regolata a livello di regioni del gene che si trovano alle sue estremità

- Promotore/Promotori
- 5'-UTR
- 3'-UTR

Study of the regulation of ACVR1 expression

- Characterization of the structure and composition of the *ACVR1* transcripts.
- Definition and characterization of sequences playing a role in the regulation of *ACVR1* expression.

✓ ***5' UTR* sequences**

Promoter region


✓ ***3' UTR* region**

Generation of a cellular model suitable for the high throughput screening of small molecules with potential pharmacological effect on the BMP/ACVR1 mediated pathway.

Study of the regulation of *ACVR1* expression

Characterization of the structure and composition of the *ACVR1* transcripts.

Definition and characterization of genomic regions playing a role in the regulation of *ACVR1* expression, such as gene promoter/s and/or other sequences with regulatory activity.



Study of the regulation of ACVR1 expression

- Characterization of the structure and composition of the *ACVR1* transcripts.
- Definition and characterization of sequences playing a role in the regulation of *ACVR1* expression.

✓ 5' UTR sequences


Promoter region

✓ 3' UTR region


Generation of a cellular model suitable for the high through-put screening of small molecules with potential pharmacological effect on the BMP/ACVR1 mediated pathway.

Characterization of the structure and composition of the *ACVR1* transcripts. How many are *ACVR1* transcripts?



The past.....



Looking at the ESTs in the *ACVR1* genomic region....The present...






ACVR1 expression profile




We have identified a new transcript isoform showing an insertion of 116 bp between the untranslated exon 2 and first protein coding exon.

This is due to an alternative splicing leading to the incorporation of 116 bp of the 5' end of intron 3 in the mRNA.

cDNA from commonly used cell lines




The inserted sequence is highly conserved among species and is even more conserved than the adjacent exon. This sequence can have a role at post-transcriptional level and we are currently investigating in this direction.





This sequence can have a role at post-transcriptional level and we are currently investigating in this direction.

About ACVR1 new putative transcripts.....



This indicates the putative presence of different transcription start sites (★) and of different transcripts showing the alternative combination of several 5'UTR exons (white rectangles) with common protein coding sequences (violet rectangles).


Expression profile of putative new isoforms




NM_001111067

DA436676


DA995330



Of Mice and Men.....and transcripts



Of Mice and Men.....and conservation



Qual è il ruolo funzionale di queste diverse regioni alternative all'estremo 5'-UTR?

C'è una regolazione differenziale per le diverse forme di mRNA?


C'è un effetto sulla stabilità del mRNA o sulla capacità di tradurre il mRNA in proteina?

Functional analysis of 5'UTR sequences



(the example of the 116 bp insertion)

Protocol

- Amplification by RT-PCR of the fragment to be tested with *NcoI* tails.
- Subcloning into the *NcoI* site of the pGL3-Promoter vector, this will cause the inclusion of the fragment under analysis in the reporter gene mRNA as 5'UTR sequence.
- Transfection in different cell lines.
- Evaluation of Luciferase activity and Real-time PCR on reporter mRNA.



NcoI *NcoI*
CCATGG 116 CCATGG Luciferase coding sequence



Commento

Il tratto di sequenza che può essere inserito nel mRNA di ACVR1 o può non esserlo esercita un effetto di inibizione dell'espressione

Study of the regulation of ACVR1 expression

- Characterization of the structure and composition of the *ACVR1* transcripts.
- Definition and characterization of sequences playing a role in the regulation of *ACVR1* expression.

✓ *5'UTR sequences*

Promoter region

✓ *3'UTR region*

Generation of a cellular model suitable for the high through-put screening of small molecules with potential pharmacological effect on the BMP/ACVR1 mediated pathway.


ACVR1: TRANSCRIPT STABILITY ANALYSIS

C2C12 cells (that normally express ACVR1), processed in the presence and absence of actinomycin D and doxorubicin (transcription inhibitors)




→ TIME COURSE with selected concentrations

→ mRNA QUANTIFICATION

Actinomicina 10 µg/ml



Doxorubicina 1 µM



ACVR1 TRANSCRIPT IS UNSTABLE

ACVR1 3'UTR

CATTTTCATA	GTGTCAAGAA	GGAAGATTG	ACGTTGTTGT	CATTGTCCAG	50
CTGGGACCTA	ATGCTGGCCT	GACTGGTTGT	CAGAATGGAA	TCCATCTGTC	100
TCCCCTCCCCA	AATGGCTGCT	TTGACAAGGC	AGACGTCGTA	CCCAGGCCATG	150
TGTTGGGGAG	ACATCAAAAC	CACCCTAACCC	TCGCTCGATG	ACTGTGAAC	200
miR-365					
GGGCATT	TCA	CGAACTGTT	ACACTGCAGA	GACTAATGTT	250
TGTTGCAAAG	GTAGGGACTG	GAGGAACACA	GAGAAATCCT	AAAAGAGATC	300
miR-365					
TGGCATT	AA	GTCAGTGGCT	TTGCATAGCT	TTCACAAGTC	350
				TCCTAGACAC	
			miR-137		
TCCCCCACGGG	AAACTCAAGG	AGGTGGTGA	TTTTTAAT CA	GCAATA TTGC	400
			miR-130a/b		
			miR-384		
CTGTGCTTCT	CTTCTTT TT	GCACTAGGAA	TTCTTGCAT	TCCTT ACTTG	450
				miR-182	
CACTG	TTACT	CTTAATT	AAGACCCAAAC	TTGCCAAA AT	500
				GTTGGCTGGC	
			miR-384		
TACTCCACTG	GTCTGTCTT	GGATAA TAGG AAT	TCAATT	GGCAAAACAA	550
			miR-30c/d/e		
AATGTAATGT	CAGACTTTGC	TGCATTTAC	ACATGTGCTG	AT GT TTACAA	600
			miR-384		
TGATGCCGAA	CAT TAGGAAT	TGTTTATACA	CAACTTGCA	AATT ATTTA T	650
TACTTGTGCA	CTTAGTAGTT	TTTACAAAAC	TGCTTGTGC	ATATGTTAAA	700
GCTTATTTT	ATGTGGTCTT	ATGATTTAT	TACAGAAATG	TTTTAACAC	750
TATACTCTAA	AATGGACATT	TTCTTTATT	ATCAGTTAAA	ATCACATT	800
miR-381/300					
AAGTGCTTCA	CAT TTGTAT	TGTGTAGACT	GTAAC	TTT	850
				TTCA	
ATGCAGAACG	TTTTA	GCC	TTACCCACGT	GACACCACCG	900
				AATATATTAC	
TG ATTTA GAA	GCAAAGATT	CAGTAGAATT	TTAGTCCTGA	ACGCTACGGG	950
GAAAATGCAT	TTTCTTCAGA	ATTATCCATT	ACGTGC ATTT A	AACTCTGCC	1000
			miR-381/300		
AGAAAAAAAT	AACTATT	TTTG	TTTAATCTA	CTT TTGTAT	1050
				TTA GTAGTTA	
TTTGTATAAA	TTAAATAAAC	TGTTTCAAG	TCAA	aaaaaaa	1100
				aaaaaaaaaa	

REGION CONTAINING miRNA



Gene silencing Positive regulation
mRNA degradation mRNA stability

REGION CONTAINING ARE Group I class 5


Possible destabilizing effect

microRNAs and proteins that bind ARE sequences could intervene in the post-transcriptional regulation of the gene.

- Regions containing miRNA and ARE sequences are subcloned in pGL-3 promoter vector and transfected in HeLa cells:

- pGL3 + miRNA region
- pGL3 + sequences ARE region

- Luciferase activity assessment




miRNA region

```
CATTTTCATA GTGTCAGAAA GGAAGATTTG ACGTTGTTGT CATTGTCAG 50
CTGGGACCTA ATGCTGGCCT GACTGGTGT CAGAATGGAA TCCATCTGTC 100
TCCCTCCCCA AATGGCTGCT TTGACAAGGC AGACGTCGTA CCCAGCCATG 150
TGTTGGGGAG ACATCAAAAC CACCTAACCC TCGCTCGATG ACTGTGAAC 200
miR-365
GGGCATT TCA CGAACTGTTT ACAC TGAGA GACTAATGTT GGACAGAC 250
TCTTGCAAAG CTAGGGACTG GAGGAACACCA GAGAAATCCT AAAAGAGAC 300
miR-365
TGGGCATT AA GTCAGTGGCT TTGCATAGCT TTCACAAGTC TCCTAGACAC 350
miR-137
TCCCCACGGG AACTCAAGG AGGTGGTGAA TTTTTAATCA GCAATA TTG 400
miR-130a/b miR-384 miR130/301/148/152
CTGTGCTTCT CTTCTTTTT GCACTAGGAA TTCTTTGCACTTACTTG 450
miR-182
CACTG TTACT CTTAATTGTTA AAGACCCAAAC TTGCCAAA AT GTTGGCTGCG 500
miR-384
TACTCCACTG GTCTGTCTTT GGATATAGG AAT TCAATTG GCAAACAA 550
miR-30c/d/e
AATGTAATGT CAGACTTGC TGCATTTAC ACATGTGCTG ATGTTTACA 600
miR-384
TGATGCCGAA CATTAGGAAT
```

ARE region

```
TGTTTATACA CAACTTTGCA AATTATTTA 650
TACCTGTGCA CTTAGTAGTT TTTACAAAAAC TGCTTGTC ATATGTTAAA 700
GCTTATTTTT ATGGGTCTT ATGATTTAT TACAGAAATG TTTTTAACAC 750
TATACTCTAA ATGGACATT TTCTTTATT ATCAGTTAA ATCACATTT 800
miR-381/300
AAGTGCTTCA CATTGTAT TGTGTAGACT GTAACCTTTT TTCAAGTTCAT 850
ATGCAGAACG ATTTA CCA TTACCCACGT GACACCACCG AATATATTAC 900
TCATTTA GAA GCAAAGATT CAGTAGAATT TTAGTCTGTA ACGCTACGGG 950
GAAAATGCAT TTTCTTCAGA ATTATCCATT ACGTGATTT AACTCTGCC 1000
miR-381/300
AGAAAAAAAT AACTATTTG TTTTAATCTA CTTTTGTAT TTAGTAGTTA 1050
TTTGATATAAA TTAAATAAAC TGTTTCAAG TCAAAaaaaaa aaaaaaaaaaa 1100
```



The presence of the 3'UTR sequences of ACVR1 causes a decreased activity of the reporter gene; transfection of the fragment containing miRNA further reduces luciferase activity.

The 3'UTR region of the ACVR1 gene may be involved in post-transcriptional regulation of ACVR1.

Role of miRNA in the regulation of ACVR1

Selection based on bioinformatics analysis considering conservation among species
and recognition by at least two different programs.

CATTTTCATA	GTGTCAAGAA	GGAAGATTG	ACGTTGTTGT	CATTGTCCAG	50
CTGGGACCTA	ATGCTGGCCT	GACTGGTTGT	CAGAACGGAA	TCCCATCTGTC	100
TCCCTCCCCA	AATGGCTGCT	TTGACAAGGC	AGACGTCGTA	CCCAGCCATG	150
TGTTGGGGAG	ACATCAAAC	CACCCTAACCC	TCGCTCGATG	ACTGTGAAC	200
miR-365					
GGGCATT	CGAACTGTT	ACACTGCAGA	GACTAATGTT	GGACAGACAC	250
TGTTGCAAAG	GTAGGGACTG	GAGGAACACA	GAGAAATCCT	AAAAGAGATC	300
miR-365					
GGGCATT	AA GTCAGTGGCT	TTGCATAGCT	TTCACAAGTC	TCCTAGACAC	350
				miR-137	
TCCCCACGGG	AAACTCAAGG	AGGTGGTGAA	TTTTTAAT CA GCAATA	TTGC	400
			miR-130a/b	miR-384	
CTGTGCTTCT	CTTCTTTATT	GCACIAGGAA	TTCTTGCAT	TCCTT ACTTG	450
				miR-182	
CACTG	TTACT	CTTAATTTA	AAGACCCAAC	TTGCCAAA AT	500
				miR-384	
TACTCCACTG	GTCTGTCTT	GGATAA TAGG AATT	GAATTATT	GGCAAAACAA	550
				miR-30c/d/e	
AATGTAATGT	CAGACTTGC	TGCATTTAC	ACATGTGCTG	AT GT TTACAA	600
				miR-384	
TGATGCCGAA	CATTAGGAAT	TGTTTATACA	CAACTTGCA	AATT ATTTAT	650
TACTTGTGCA	CTTAGTAGTT	TTTACAAAAC	TGCTTTGTGC	ATATGTTAAA	700
GCTTATTTTT	ATGTGGTCTT	ATGATTTAT	TACAGAAATG	TTTTAACAC	750
TATACTCTAA	ANTGGACATT	TTCTTTATT	ATCAGTTAAA	ATCACATT	800
				miR-381/300	
AAGTGCTTCA	CATTTGTATG	TGTGTAGACT	GTAACTTTT	TTCAGTTCAT	850
ATGCAGAACG	ATTTA GCCA	TTACCCACGT	GACACCACCG	AATATATTAC	900
TG ATTTA GAA	GCAAAGATT	CAGTAGAATT	TTAGTCCTGA	ACGCTACGGG	950
GAAAATGCAT	TTCTTCAGA	ATTATCCATT	ACGTGC ATTT	AAACTCTGCC	1000
				miR-381/300	
AGAAAAAAAT	AACTATTTG	TTTAATCTA	CTTT TTGTAT ITA	GTAGTTA	1050
TTTGTATAAA	TTAAATAAAC	TGTTTCAAG	TCAAAaaaaaa	aaaaaaaaaaa	1100

What about miRNA selected...

miR-365: Regulates cell proliferation, resulting down-regulated in arrest of proliferation, senescence and quiescence. From the clinical point of view it is overexpressed in cases of breast cancer.

miR-148b: is involved in the mechanisms of bone generation, is essential for regulating the process of osteogenesis: has been shown that it up-regulates the osteogenic differentiation of mesenchymal stem cells.

miR-384: as observed in different cell lines it has a protective role against the induction of apoptosis.


miR-381: is a candidate for the control of dendritic development and spine, has been shown that its expression is essential for dendritic outgrowth of hippocampal neurons.

TRANSFECTION through nucleofection : - control negative Cy3
 - Pre-miR,
 - Anti-miR
 - co-transfection Pre-miR+Anti-miR


miR 365 assay

HeLa

24H



48H




Gene Expression : RIEPILOGO_2009-10-
 26_1208.opd

Gene Expression : RIEPILOGO_2009-10-
 26_1208.opd


miR 148b assay

HeLa

24H



48H




Gene Expression : ANALISIData 2009-11-30
1124.opd

Gene Expression : ANALISIData 2009-11-30
1124.opd


miR 381 assay

HeLa

24H



48H




Gene Expression : ANALISIData 2010-01-15
1458.opd

Gene Expression : ANALISIData 2010-01-15
1458.opd


miR 384 assay

HeLa

24H




48H




Gene Expression : ANALISIData 2010-02-19
1044.opd

Gene Expression : ANALISIData 2010-02-19
1044.opd

- Co-transfection of ACVR1 3'UTR and selected miRNA
- Luciferase activity assessment



The miR-148b presence reduces further the reporter gene activity induced by the 3'UTR of ACVR1. His antagonist anti-miR restores the effect induced by the 3'UTR only.



The miR-365 presence further reduces the decrease of the reporter gene induced by the 3'UTR of ACVR1.

Commento

Nella regione 3'-UTR si esercita un regolazione dell'espressione in termini di inibizione dell'espressione.

Alcuni microRNA che riconoscono sequenze nel 3'-UTR sembrano agire come inibitori.

Un obiettivo ambizioso

Trovare dei composti chimici che esercitano un effetto di
inibizione sulla funzione della via delle BMP

Bisogna mettere a punto un metodo di analisi

US agencies collaborate to speed up innovative drug development



In the United States, the Food and Drug Administration (FDA) and the National Institutes of Health (NIH) have embarked upon an initiative that will accelerate the journey of bringing innovative medicinal products to market. The new collaboration twines translational research with regulatory science - both key to transforming "*biomedical discoveries into products that benefit people*". A Joint NIH-FDA Leadership Council will oversee the initiative to "*help ensure that regulatory considerations form an integral component of biomedical research planning and that the latest science is integrated into the regulatory review process*". A Request for Applications that will make \$USD 6.75 million available over three years will be issued. A press release states that the "*research supported through this initiative should add to the scientific knowledge base by providing new methods, models or technologies that will inform the scientific and regulatory community about better approaches to evaluating safety and efficacy in medical product development*". Orphan drugs represent some 20% of all innovative products.

orphaNews Europe, 7 Aprile 2010

Due importanti Agenzie negli Stati Uniti, NIH e FDA, collaborano per accelerare lo sviluppo di farmaci innovativi

Study of the regulation of ACVR1 expression

- Characterization of the structure and composition of the *ACVR1* transcripts.
- Definition and characterization of sequences playing a role in the regulation of *ACVR1* expression.


✓ *5'UTR sequences*

Promoter region



✓ *3'UTR region*

Generation of a cellular model suitable for the high through-put screening of small molecules with potential pharmacological effect on the BMP/ACVR1 mediated pathway.


A) Generation of stable cell lines expressing both ACVR1/ALK2 receptor (wild-type and mutated form) and the reporter gene (EGFP) controlled by a BMP responsive element in C2C12 cells.




Check for the ACVR1 construct expression by WB analysis



The effect of the tested molecules on the BMP-ACVR1 pathway is evaluated with a plate-reader instrument through the detection and measurement of the fluorescent signal emitted by the reporter gene, directly on living cells.



A) Generazione sistema cellulare
Introduzione del recettore
ACVR1/ALK2 mutato (stella rossa) e
del gene reporter (EGFP) controllato
da un elemento responsivo
all'attivazione delle BMP (BRE-EGFP)
in cellule C2C12.



B) Trattamento delle cellule così ottenute con una libreria di molecole farmacologiche in presenza e assenza di stimolazione con BMP e valutazione del loro effetto in termini di variazione nella emissione di fluorescenza.

